Market Spotlight: Systemic Hypertension
Market Spotlight: Systemic Hypertension
This Market Spotlight report covers the Systemic Hypertension market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2017, there were approximately 1.7 billion prevalent cases of systemic hypertension worldwide, and forecasts that number to increase to 1.9 billion prevalent cases by 2026.
- Systemic hypertension has a slight male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 53.31% of cases aged 25 years and over were male.
- The approved drugs in the systemic hypertension space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with a few products being available in intravenous, intramuscular, and transdermal formulations.
- The largest proportion of industry-sponsored drugs in active clinical development for systemic hypertension are in Phase I, with only one drug in the NDA/BLA phase.
- Therapies in development for systemic hypertension focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being intranasal, subcutaneous, intravenous, and topical formulations.
- The overall likelihood of approval of a Phase I systemic hypertension asset is 6.4%, and the average probability a drug advances from Phase III is 68.2%. Drugs, on average, take 6.5 years from Phase I to approval, compared to 9.8 years in the overall cardiovascular space.
- There have been 38 licensing and asset acquisition deals involving hypertension drugs during 2014–19. The largest deal was the $792m exclusive agreement between The Medicines Company and Chiesi in 2016 for the sale of Cleviprex injectable emulsion, Kengreal, and the rights to argatroban for injection.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for hypertension have been in the late phases of development, with 53% of trials in Phase III–IV, and 47% in Phase I–II.
- The US has a substantial lead in the number of hypertension clinical trials globally. Germany leads the major EU markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the hypertension space is dominated by completed trials. Novartis has the highest number of completed clinical trials for hypertension, with 384 trials. Novartis also leads industry sponsors with by far the highest overall number of clinical trials for hypertension.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 Pharmacological therapy
13 MARKETED DRUGS
26 PIPELINE DRUGS
32 RECENT EVENTS AND ANALYST OPINION
32 CIN-107 for Systemic Hypertension (May 14, 2019)
33 Firibastat for Systemic Hypertension (November 11, 2018)
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 CinCor Licenses Roche Hypertension Candidate, Raises $50m
39 PARENT PATENTS
40 REVENUE OPPORTUNITY
44 CLINICAL TRIAL LANDSCAPE
45 Sponsors by status
46 Sponsors by phase
47 Recent events
48 Prescription information
LIST OF FIGURES
11 Figure 1: Trends in prevalent cases of systemic hypertension, 2017–26
26 Figure 2: Overview of pipeline drugs for systemic hypertension in the US
27 Figure 3: Pipeline drugs for systemic hypertension, by company
27 Figure 4: Pipeline drugs for systemic hypertension, by drug type
28 Figure 5: Pipeline drugs for systemic hypertension, by classification
35 Figure 6: Firibastat for Systemic Hypertension (November 11, 2018): Phase IIb – NEW-HOPE
36 Figure 7: Probability of success in the systemic hypertension pipeline
37 Figure 8: Licensing and asset acquisition deals in systemic hypertension, 2014–19
39 Figure 9: Parent patents in systemic hypertension, 2019–24
39 Figure 10: Parent patents in systemic hypertension, 2025–36
44 Figure 11: Clinical trials in hypertension
44 Figure 12: Top 10 drugs for clinical trials in hypertension
45 Figure 13: Top 10 companies for clinical trials in hypertension
45 Figure 14: Trial locations in hypertension
46 Figure 15: Hypertension trials status
47 Figure 16: Hypertension trials sponsors, by phase
LIST OF TABLES
10 Table 1: Prevalent cases of systemic hypertension (000s), 2017–26
12 Table 2: Prevalent cases of systemic hypertension (000s), by gender, 2017
14 Table 3: Marketed drugs for systemic hypertension
29 Table 4: Pipeline drugs for systemic hypertension in the US
32 Table 5: CIN-107 for Systemic Hypertension (May 14, 2019)
33 Table 6: Firibastat for Systemic Hypertension (November 11, 2018)
41 Table 7: Historical global sales, by drug ($m), 2014–18
43 Table 8: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.